Moreover, we demonstrated that SLC25A32 activates the PI3K-AKT signaling pathway in GBM cells to maintain malignant phenotype, suggesting that SLC25A32 is a potential therapeutic target in GBM. Here, SLC25A32 is linked to glioblastoma.